Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial

Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz Dotzer; Michael Dommasch; Sebastian Kufner; Kathrin A. Birkmeier; Klaus Tiroch; Robert A. Byrne; Albert Schömig; Adnan Kastrati

首页> 外文期刊>Clinical Research in Cardiology >Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial

【24h】

Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial

机译：阿昔单抗对氯吡格雷预处理后非ST段抬高的急性冠脉综合征PCI患者左心功能演变的影响：ISAR-REACT 2试验的经验教训

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Abciximab reduced the combined endpoint of death, myocardial infarction (MI) and target vessel revascularization in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation after a 600-mg loading dose of clopidogrel. The aim of the present study was to investigate the impact of abciximab on the evolution of left ventricular ejection fraction (LVEF) in these patients.

机译：在600 mg负荷后接受经皮冠状动脉介入治疗（PCI）并经支架置入的非ST段抬高急性冠脉综合征（NSTE-ACS）患者中，Abciximab降低了死亡，心肌梗死（MI）和靶血管血运重建的综合终点氯吡格雷的剂量。本研究的目的是调查阿昔单抗对这些患者左心室射血分数（LVEF）演变的影响。

著录项

来源
《Clinical Research in Cardiology》 |2011年第8期|p.691-699|共9页
作者
Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz Dotzer; Michael Dommasch; Sebastian Kufner; Kathrin A. Birkmeier; Klaus Tiroch; Robert A. Byrne; Albert Schömig; Adnan Kastrati;
展开▼
作者单位

Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany;

Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany;

Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany;

Klinikum Garmisch-Partenkirchen, Zentrum für Innere Medizin/Kardiologie, Auenstraße 6, 82467, Garmisch-Partenkirchen, Germany;

Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany;

Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany;

Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany;

Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany;

Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany;

Deutsches Herzzentrum, Technische;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Abciximab; Heparin; Clopidogrel; Stent; LV function;

机译：阿昔单抗;肝素;氯吡格雷;支架;左室功能;

相似文献

外文文献
中文文献
专利

1. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. [J] . Ndrepepa G, Kastrati A, Mehilli J, European Heart Journal: The Journal of the European Society of Cardiology . 2008,第4期

机译：氯吡格雷预治疗后接受经皮冠状动脉介入治疗的非ST段抬高的急性冠状动脉综合征的患者接受abciximab与安慰剂的一年临床疗效：ISAR-REACT 2随机试验的结果。
2. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial† [J] . Gjin Ndrepepa1 Adnan Kastrati1* Julinda Mehilli1 Franz-Josef Neumann2 Jurriën ten Berg3 Olga Bruskina1 Franz Dotzer4 Melchior Seyfarth1 Jürgen Pache1 Josef Dirschinger5 Peter B. Berger6 and Albert Schömig15 European Heart Journal . 2008,第4期

机译：对于非ST段抬高的急性冠状动脉综合征，在接受氯吡格雷治疗后接受经皮冠状动脉介入治疗的患者，用阿昔单抗和安慰剂进行一年临床疗效：ISAR-REACT 2随机试验的结果†
3. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. [J] . Kastrati A, Mehilli J, Neumann FJ, JAMA: the Journal of the American Medical Association . 2006,第13期

机译：氯吡格雷预处理后接受经皮冠状动脉介入治疗的急性冠脉综合征患者的阿昔单抗：ISAR-REACT 2随机试验。
4. Evaluation of prognosis and left ventricular function in non ST elevation acute coronary syndrome with residual vascular risk [C] . Bobescu E., Radoi M., Datcu G., International Congress on Coronary Artery Disease . 2009

机译：非St升高急性冠状动脉综合征的预后和左心室功能评价，残留血管风险
5. The use of transesophageal echocardiography for the assessment of left ventricular volume and function in patients undergoing acute normovolemic hemodilution as a human hemorrhagic model. [D] . Rose, David D. 2007

机译：经食道超声心动图评估急性降血容量血液稀释患者的左室容量和功能，作为人类出血模型。
6. Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics [O] . Timm Bauer, Helge Möllmann, Franz Weidinger, -1

机译：血小板糖蛋白IIb / IIIa抑制剂在接受PCI治疗的非ST段抬高的急性冠脉综合征的糖尿病患者中的使用：对临床状况和程序特征的影响
7. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial [O] . G. Ndrepepa, A. Kastrati, J. Mehilli, 2008

机译：与Abciximab与安慰剂的一年临床结果与氯吡格雷预处理后经皮冠状动脉综合征的急性冠状动脉综合征患者：ISAR反应2随机试验的结果

Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial

摘要

著录项

相似文献

相关主题

期刊订阅